请输入您要查询的百科知识：

　

词条 Protease inhibitor (pharmacology)
释义

  1. Antiretrovirals

  2. Antiprotozoal activity

  3. Anticancer activity

  4. Side effects

  5. See also

  6. References

  7. External links

{{for|natural protease inhibitors|protease inhibitor (biology)}}

Protease inhibitors (PIs) are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis C. Protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles.

Protease inhibitors that have been developed and are currently used in clinical practice include:

{{div col|colwidth=30em}}
  • Antiretroviral HIV-1 protease inhibitors — class stem –navir[1]{{rp|23}}
    • amprenavir
    • atazanavir
    • darunavir
    • fosamprenavir
    • indinavir
    • lopinavir
    • nelfinavir
    • ritonavir
    • saquinavir
    • tipranavir
  • Hepatitis C virus NS3/4A protease inhibitors — class stem –previr[1]{{rp|26}}
    • asunaprevir
    • boceprevir
    • grazoprevir
    • paritaprevir
    • simeprevir
    • telaprevir
{{div col end}}

Given the specificity of the target of these drugs there is the risk, as in antibiotics, of the development of drug-resistant mutated viruses. To reduce this risk it is common to use several different drugs together that are each aimed at different targets.

Antiretrovirals

Protease inhibitors were the second class of antiretroviral drugs developed. The first members of this class, saquinavir and ritonavir, were approved in late 1995–1996. Within 2 years, annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000[2] Prior to this the annual death rate had been increasing by approximately 20% each year.

Name Trade name Company Patent FDA approval date Notes
Saquinavir Invirase, Fortovase Hoffmann–La Roche 5196438}} December 6, 1995 The first protease inhibitor approved by the U.S. Food and Drug Administration (FDA).
Ritonavir Norvir Abbott 5541206}} March 1, 1996 —
Indinavir Crixivan Merck & Co. 5413999}} March 13, 1996 —
Nelfinavir Viracept Hoffmann–La Roche 5484926}} March 14, 1997 —
Amprenavir Agenerase GlaxoSmithKline 5585397}} April 15, 1999 The sixteenth FDA-approved antiretroviral. It was the first protease inhibitor approved for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 very large gel capsules. Production was discontinued by the manufacturer December 31, 2004, as it has been superseded by fosamprenavir.
Lopinavir Kaletra Abbott 5914332}} September 15, 2000 Is only marketed as a fixed-dose combination with ritonavir (see lopinavir/ritonavir).
Atazanavir Reyataz Bristol-Myers Squibb 5849911}} June 20, 2003 Atazanavir was the first PI approved for once-daily dosing. It appears to be less likely to cause lipodystrophy and elevated cholesterol as side effects. It may also not be cross-resistant with other PIs.
Fosamprenavir Lexiva, Telzir GlaxoSmithKline — October 20, 2003 A prodrug of amprenavir. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow release version of amprenavir and thus reduces the number of pills required versus standard amprenavir.
Tipranavir Aptivus Boehringer Ingelheim — June 22, 2005 Also known as tipranavir disodium.
Darunavir Prezista Janssen Therapeutics 6248775}} June 23, 2006 As of 2016, darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents.[3] Several ongoing phase III trials are showing a high efficiency for the darunavir/ritonavir combination being superior to the lopinavir/ritonavir combination for first-line therapy.[4] Darunavir is the first drug in a long time that didn't come with a price increase. It leapfrogged two other approved drugs of its type, and is matching the price of a third.[5][6][7]

Antiprotozoal activity

Researchers are investigating the use of protease inhibitors developed for HIV treatment as anti-protozoals for use against malaria and gastrointestinal protozoal infections:

  • A combination of ritonavir and lopinavir was found to have some effectiveness against Giardia infection.[8]
  • The drugs saquinavir, ritonavir, and lopinavir have been found to have anti-malarial properties.[9]
  • A cysteine protease inhibitor drug was found to cure Chagas disease in mice.[10]

Anticancer activity

Researchers are investigating whether protease inhibitors could possibly be used to treat cancer. For example, nelfinavir and atazanavir are able to kill tumor cells in culture (in a Petri dish).[11][12] This effect has not yet been examined in humans; but studies in laboratory mice have shown that nelfinavir is able to suppress the growth of tumors in these animals, which represents a promising lead towards testing this drug in humans as well.[12]

Inhibitors of the proteasome, such as bortezomib are now front-line drugs for the treatment of multiple myeloma.

Tanomastat is one of the matrix metalloproteinase inhibitors that can be used to treat cancer.

Side effects

Protease inhibitors can cause a syndrome of lipodystrophy, hyperlipidemia, diabetes mellitus type 2, and kidney stones.[13] This lipodystrophy is colloquially known as "Crix belly", after indinavir (Crixivan).[14]

See also

  • The Proteolysis Map
  • Reverse transcriptase inhibitor
  • Discovery and development of NS5A inhibitors

References

1. ^1 {{cite web|title=The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances|url=http://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf|publisher=World Health Organization|accessdate=5 November 2016}}
2. ^{{Cite web | title = HIV Surveillance --- United States, 1981--2008 | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm | accessdate = 8 November 2013 }}
3. ^{{cite web | title = Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents | url = https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf | publisher = Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents — A Working Group of the Office of AIDS Research Advisory Council (OARAC) | accessdate = 5 November 2016 | date=July 14, 2016}}
4. ^{{cite journal |author=Madruga JV |title=Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial |journal=Lancet |volume=370 |issue=9581 |pages=49–58 |date=Jul 2007 |pmid=17617272 |doi=10.1016/S0140-6736(07)61049-6 |url= |name-list-format=vanc|author2=Berger D |author3=McMurchie M |display-authors=3 |last4=Suter |first4=Fredy |last5=Banhegyi |first5=Denes |last6=Ruxrungtham |first6=Kiat |last7=Norris |first7=Dorece |last8=Lefebvre |first8=Eric |last9=De Béthune |first9=Marie-Pierre}}
5. ^Liz Highleyman, Patient Advocates Commend Pricing of New PI Darunavir, http://www.hivandhepatitis.com/recent/2006/ad1/063006_a.html
6. ^Darunavir - first molecule to treat drug-resistant HIV
7. ^{{cite journal |author=Borman S |title=Retaining Efficacy Against Evasive HIV: Darunavir analog to AIDS-virus shapeshifters: Resistance may be futile |journal=Chemical & Engineering News |volume=84 |issue=34 |pages=9 |year=2006 |url=http://pubs.acs.org/cen/news/84/i34/8434drugdesign.html |doi=10.1021/cen-v084n034.p009 }}
8. ^{{cite journal |author=Dunn LA |title=The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis |journal=Int. J. Antimicrob. Agents |volume=29 |issue=1 |pages=98–102 |year=2007 |pmid=17137752 |doi=10.1016/j.ijantimicag.2006.08.026 |name-list-format=vanc|author2=Andrews KT |author3=McCarthy JS |display-authors=3 |last4=Wright |first4=Janelle M. |last5=Skinner-Adams |first5=Tina S. |last6=Upcroft |first6=Peter |last7=Upcroft |first7=Jacqueline A.}}
9. ^{{cite journal |author=Andrews KT |title=Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria |journal=Antimicrob. Agents Chemother. |volume=50 |issue=2 |pages=639–48 |year=2006 |pmid=16436721 |doi=10.1128/AAC.50.2.639-648.2006 |pmc=1366900 |name-list-format=vanc|author2=Fairlie DP |author3=Madala PK |display-authors=3 |last4=Ray |first4=J. |last5=Wyatt |first5=D. M. |last6=Hilton |first6=P. M. |last7=Melville |first7=L. A. |last8=Beattie |first8=L. |last9=Gardiner |first9=D. L.}}
10. ^{{cite journal |vauthors=Doyle PS, Zhou YM, Engel JC, McKerrow JH |title=A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection |journal= Antimicrobial Agents and Chemotherapy|volume= 51|issue= 11|pages=3932–9|year=2007 |pmid=17698625 |doi=10.1128/AAC.00436-07 |pmc=2151429}}
11. ^{{cite journal|url=http://clincancerres.aacrjournals.org/cgi/content/abstract/13/17/5183|author= J.J. Gills |title=Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo|journal= Clinical Cancer Research |volume=13|pages=5183–94|year=2007 |doi=10.1158/1078-0432.CCR-07-0161 |pmid=17785575|issue=17|name-list-format=vanc|display-authors=1|last2=Lopiccolo|first2=J.|last3=Tsurutani|first3=J.|last4=Shoemaker|first4=R. H.|last5=Best|first5=C. J.M.|last6=Abu-Asab|first6=M. S.|last7=Borojerdi|first7=J.|last8=Warfel|first8=N. A.|last9=Gardner|first9=E. R.}}
12. ^1 {{cite journal|url= |title=HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress|journal= Cancer Research |volume=67|pages=10920–8|year=2007 |doi=10.1158/0008-5472.CAN-07-0796 |author=Pyrko, P. |pmid=18006837|last2= Kardosh|first2= A|last3= Wang|first3= W|last4= Xiong|first4= W|last5= Schönthal|first5= AH|last6= Chen|first6= TC|issue= 22}}
13. ^{{cite journal|pmid=12626882|year=2003|last1=Fantry|first1=LE|title=Protease inhibitor-associated diabetes mellitus: A potential cause of morbidity and mortality|volume=32|issue=3|pages=243–4|journal=Journal of Acquired Immune Deficiency Syndromes|doi=10.1097/00126334-200303010-00001}}
14. ^{{cite journal | title=Protease inhibitors' metabolic side effects: cholesterol, triglycerides, blood sugar, and "Crix belly" | journal=AIDS Treatment News | issue=277 | pages=1–4 | year=1997 | pmid=11364559 | last1=Capaldini | first1=L. }}

External links

  • A brief history of the development of protease inhibitors by Hoffman La Roche, Abbott, and Merck
  • [https://aidsinfo.nih.gov/guidelines HIV/AIDS Treatment Guidelines] US Department of Health and Human Services
{{HIVpharm}}{{RNA antivirals}}{{Enzyme inhibition}}{{DEFAULTSORT:Protease Inhibitor (Pharmacology)}}ProteaseinhibitorInhibiteur de la protéase

1 : Protease inhibitors
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/11 9:47:13